Acquisitions, Divestitures, Equity-Method Investments, Licensing Arrangement, Collaborative Arrangements and Research and Development Arrangement - Equity Method Investments (Details) € in Millions, £ in Millions		1 Months Ended		12 Months Ended
		Jul. 31, 2022 USD ($)	Jul. 31, 2022 GBP (£)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 03, 2022 USD ($)	Jul. 03, 2022 GBP (£)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Mar. 31, 2022 GBP (£)	Dec. 31, 2019 USD ($)	Jul. 31, 2019	Dec. 31, 2016 USD ($)
Schedule of Equity Method Investments [Line Items]
Equity-method investments				$ 11,637,000,000	$ 11,033,000,000
Other short-term borrowings	[1]			252,000,000	385,000,000
Dividend received, return of capital	[2]			$ 0	3,960,000,000	$ 0
1.365% Consumer Healthcare JV Loan [Member] | Loans Payable [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | £								£ 2,900
Other short-term borrowings							$ 3,700,000,000
Stated interest rate							1.365%	1.365%
Repurchased debt | £			£ 2,900
Haleon [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				32.00%
Haleon/Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage									32.00%	32.00%	32.00%
Equity-method investments				$ 11,500,000,000	10,800,000,000
Equity-method investment, quoted market value				12,100,000,000
Dividend received, distribution				153,000,000
Decrease due to foreign currency translation				280,000,000
Equity method investment earnings				$ 489,000,000	536,000,000	495,000,000
Equity method investment, adjustment of basis differences					100,000,000
Dividend received, return of capital		$ 4,000,000,000
Dividends received, total		$ 4,200,000,000	£ 3,500
Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Difference between carrying amount and underlying equity												$ 4,800,000,000
ViiV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage				11.70%
Equity-method investments														$ 0
Dividend income				$ (265,000,000)	$ (314,000,000)	$ (166,000,000)
GSK [Member] | Haleon/Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage													68.00%
Haleon/Consumer Healthcare JV [Member] | Senior Notes, USD Denominated [Member] | Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount									$ 8,750,000,000
Haleon/Consumer Healthcare JV [Member] | Senior Notes, EUR Denominated [Member] | Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | €										€ 2,350
Haleon/Consumer Healthcare JV [Member] | Senior Notes, GBP Denominated [Member] | Senior Notes [Member]
Schedule of Equity Method Investments [Line Items]
Debt instrument, face amount | £											£ 700
Haleon/Consumer Healthcare JV [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | GSK [Member]
Schedule of Equity Method Investments [Line Items]
Proposed percent of ownership disposal									80.00%	80.00%	80.00%
Minimum [Member] | Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization period				8 years
Maximum [Member] | Consumer Healthcare JV [Member]
Schedule of Equity Method Investments [Line Items]
Excess basis amortization period				20 years

[1] Primarily includes cash collateral. See Note 7F.

[2] See Note 2C.